UMIN-CTR Clinical Trial

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000041967
Receipt No. R000047907
Scientific Title Prognostic factor analysis by integrating JALSG clinical trials using TKIs for Ph+ALL with TRUMP data
Date of disclosure of the study information 2020/10/07
Last modified on 2022/06/30 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Prognostic factor analysis by integrating JALSG clinical trials using TKIs for Ph+ALL with TRUMP data
Acronym JALSG Ph+ALL TKI-SCT study
Scientific Title Prognostic factor analysis by integrating JALSG clinical trials using TKIs for Ph+ALL with TRUMP data
Scientific Title:Acronym JALSG Ph+ALL TKI-SCT study
Region
Japan

Condition
Condition Philadelphia chromosome-positive acute lymphoblastic leukemia
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To identify prognostic factors in Ph+ALL patients who treated with tyrosine kinase inhibitors.
Basic objectives2 Others
Basic objectives -Others Identification of prognostic factors
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To identify risk factors for overall survival
Key secondary outcomes - To identify risk factors for relapse
- To identify risk factors for non-relapse mortality
- To identify prognostic factors in allogenic hematopoietic cell transplantation
- To identify prognostic factors in non-transplant patients
- Survival rate, relapse rate, and non-relapse mortality according to identified factors
- Indication of allogeneic hematopoietic cell transplantation in the first complete remission

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
64 years-old >=
Gender Male and Female
Key inclusion criteria Patients who have enrolled in the JALSG Ph+ALL202 study, 208 study, or 213 study
Key exclusion criteria Patients rejected the enrollment
Target sample size 246

Research contact person
Name of lead principal investigator
1st name Satoshi
Middle name
Last name Nishiwaki
Organization Nagoya University Hospital
Division name Department of Advanced Medicine
Zip code 4668560
Address 65 Tsurumai-cho Showa-ku, Nagoya
TEL 052-744-2942
Email n-3104@med.nagoya-u.ac.jp

Public contact
Name of contact person
1st name Satoshi
Middle name
Last name Nishiwaki
Organization Nagoya University Hospital
Division name Department of Advanced Medicine
Zip code 4668560
Address 65 Tsurumai-cho Showa-ku, Nagoya
TEL 052-744-2942
Homepage URL
Email n-3104@med.nagoya-u.ac.jp

Sponsor
Institute Nagoya University
Institute
Department

Funding Source
Organization Nagoya University
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Nagoya University Hospital
Address 65 Tsurumai-cho Showa-ku, Nagoya
Tel 052-744-2061
Email iga-shinsa@adm.nagoya-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 10 Month 07 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 206
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2020 Year 04 Month 13 Day
Date of IRB
2020 Year 09 Month 30 Day
Anticipated trial start date
2020 Year 10 Month 07 Day
Last follow-up date
2027 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Pooled analysis of JALSG Ph+ALL202 study, Ph+ALL208 study, and Ph+ALL213 study.

Management information
Registered date
2020 Year 10 Month 01 Day
Last modified on
2022 Year 06 Month 30 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047907